0000000000067560

AUTHOR

Moshe Ben-shoshan

showing 6 related works from this author

The global impact of the COVID-19 pandemic on the management and course of chronic urticaria

2021

Introduction: the COVID-19 pandemic dramatically disrupts health care around the globe. The impact of the pandemic on chronic urticaria (CU) and its management are largely unknown. Aim: to understand how CU patients are affected by the COVID-19 pandemic; how specialists alter CU patient management; and the course of CU in patients with COVID-19. Materials and methods: our cross-sectional, international, questionnaire-based, multicenter UCARE COVID-CU study assessed the impact of the pandemic on patient consultations, remote treatment, changes in medications, and clinical consequences. Results: the COVID-19 pandemic severely impairs CU patient care, with less than 50% of the weekly numbers o…

Male0301 basic medicineSTRESSExacerbationUCAREpandemijeMedizinOmalizumabOmalizumabSERUMchronic urticaria0302 clinical medicinePandemicHealth careImmunology and AllergyChronic UrticariatreatmentChronic urticaria; COVID-19; Cyclosporine; Omalizumab; Pandemic; SARS-CoV-2; Treatment; UCAREzdravljenjeASSOCIATIONMiddle AgedCOVID-19; SARS-CoV-2; UCARE; chronic urticaria; cyclosporine; omalizumab; pandemic; treatmentkronična urtikarijaINFECTIONSGA(2)LENCyclosporineFemale600 Technik Medizin angewandte Wissenschaften::610 Medizin und Gesundheit::610 Medizin und Gesundheitmedicine.drugAdultmedicine.medical_specialtyAdolescentCoronavirus disease 2019 (COVID-19)Immunology610udc:616-097pandemicsciklosporinYoung Adult03 medical and health sciencesPatient referralmedicineHumansIn patientPatient Reported Outcome MeasurescyclosporineChronic urticariaAgedInternetPandemicSARS-CoV-2business.industrypandemicCOVID-19TreatmentDEFINITIONMedicine; Allergy; ImmunologyCross-Sectional Studies030104 developmental biology030228 respiratory systemEmergency medicineomalizumabbusinessAllergy: European Journal of Allergy and Clinical Immunology
researchProduct

The global burden of chronic urticaria for the patient and society*

2020

Chronic urticaria (CU) affects about 1% of the world population of all ages, mostly young and middle-aged women. It usually lasts for several years (> 1 year in 25-75% of patients) and often takes > 1 year before effective management is implemented. It presents as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) or both in the same person. More than 25% of cases are resistant to H1 -antihistamines, even at higher doses, and third- and fourth-line therapies (omalizumab and ciclosporin) control the disease only in two-thirds of H1 -antihistamine-resistant patients. Here we review the impact of CU on different aspects of patients' quality of life and the burden of this …

Pediatricsmedicine.medical_specialtyUrticariaOmalizumabDermatologyOmalizumabDisease030207 dermatology & venereal diseases03 medical and health sciencesIndirect costs0302 clinical medicineQuality of lifemedicineHumansChronic UrticariaDepression (differential diagnoses)business.industryUrticària -- TractamentDermatology Life Quality IndexMiddle AgedSalut públicaEuropeSexual dysfunctionQualitat de vidaChronic DiseasePresenteeismQuality of LifeIndicadors econòmicsFemalemedicine.symptombusinessmedicine.drugBritish Journal of Dermatology
researchProduct

Management of Chronic Urticaria in a Pediatric Population

2019

Pediatricsmedicine.medical_specialtybusiness.industryImmunologyImmunology and AllergyMedicinebusinessChronic urticariaPediatric populationJournal of Allergy and Clinical Immunology
researchProduct

The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria

2022

This update and revision of the international guideline for urticaria was developed following the methods recommended by Cochrane and the Grading of Recommendations Assessment, Development and Evaluation (GRADE) working group. It is a joint initiative of the Dermatology Section of the European Academy of Allergology and Clinical Immunology (EAACI), the Global Allergy and Asthma European Network (GALEN) and its Urticaria and Angioedema Centers of Reference and Excellence (UCAREs and ACAREs), the European Dermatology Forum (EDF; EuroGuiDerm), and the Asia Pacific Association of Allergy, Asthma and Clinical Immunology with the participation of 64 delegates of 50 national and international soci…

medicine.medical_specialtyEvidence-based practicehivesmedia_common.quotation_subjectImmunologyeducation610DermatologyAngioedema/diagnosis030207 dermatology & venereal diseases03 medical and health sciencesurticaria0302 clinical medicineQuality of lifeExcellenceimmune system diseasesevidence-basedparasitic diseasesmedicinePrevalenceImmunology and Allergymedia_common.cataloged_instanceHumansitchEuropean unionskin and connective tissue diseaseswhealAsthmamedia_commonAngioedemabusiness.industryangioedemaConsensus conferenceGUIDELINES ; angioedema ; consensus ; evidence2̆010based ; hives ; itch ; mast cell ; urticaria ; whealGuidelinemedicine.diseaseAsthma3. Good healthddc:030228 respiratory systemconsensusFamily medicineChronic DiseaseQuality of LifeUrticaria/diagnosismedicine.symptombusinessmast cell600 Technik Medizin angewandte Wissenschaften::610 Medizin und Gesundheit::610 Medizin und Gesundheit
researchProduct

Urticaria in Pediatrics and During Pregnancy and Lactation: Highlights on Epidemiology, Diagnosis, and Management

2021

Chronic urticaria (CU) in children as in adults is characterized by the presence of itchy wheals, angioedema, or both daily or almost daily for at least 6 weeks. Most cases of urticaria in the pediatric age group are acute [1–4]. CU is sub-classified as spontaneous (occurring without a known trigger) or inducible. There are also cases of spontaneous and inducible forms that co-exist. The chronic subtypes occur continuously but also recurrently, often in association with infections. In this chapter we will touch briefly on the clinical presentation, diagnosis, and management of acute urticaria in children. However, our primary goal is to highlight key findings regarding the epidemiology, dia…

PregnancyPediatricsmedicine.medical_specialtyAcute urticariaAngioedemabusiness.industryPediatric agemedicine.diseasemedicine.anatomical_structureimmune system diseasesLactationEpidemiologyMedicineApproaches of managementmedicine.symptomskin and connective tissue diseasesbusinessChronic urticaria
researchProduct

Definition, aims, and implementation of GA [sup] 2 LEN/HAEi Angioedema Centers of Reference and Excellence

2020

This document summarizes the aims of GA2 LEN/HAEi Angioedema Centers of Reference and Excellence (ACAREs) and elaborates the requirements that ACAREs must fulfill to become certified. It also provides (see Appendix S1) background information on GA2LEN and HAEi, including HAEi member organizations and regional patient advocates, on why we need an Angioedema Center of Reference and Excellence (ACARE) program and network, and on the accreditation and certification process, governance and funding, and on the interaction with other GA2LEN networks of centers of reference and excellence. The protocols, aims, requirements, and provisions related to becoming a certified CARE are based on (a) the ex…

medicine.medical_specialtyEdema angioneuròticUrticariamedia_common.quotation_subjectImmunologyeducationGA2LENAngioedema; Center; Excellence; Management; Urticariaurticariacentres of reference and excelenceExcellenceimmune system diseasescentermedicineImmunology and AllergyCenter (algebra and category theory)Angioneurotic edemaskin and connective tissue diseasesmedia_commonudc:616.1Angioedemabusiness.industryangioedemahumanitiesreferenčni centri odličnostiMedicine; Allergy; ImmunologyFamily medicineexcellencemedicine.symptombusinessGlobal Allergy and Asthma European NetworkUrticàriamanagement
researchProduct